Baidu
map

研究设计与统计

订阅

MedSci主页 / 所有栏目 / 研究设计与统计

Graphpad Prism和SPSS的分析结果有差异怎么办？

2021-08-09 MedSci原创 MedSci原创

Graphpad Prism
关注

Graphpad Prism和SPSS的分析结果有差异，应该怎么选择-Graphpad Prism快速作图技巧_2

《梅斯直播课——SCI大神在线：Graphpad Prism快速作图技巧》

回答问题2：Graphpad Prism和SPSS的分析结果有差异，应该怎么选择？

 

欢迎点赞、评论、分享

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2069215, encodeId=f56f206921548, content=<a href='/topic/show?id=519b1420696' target=_blank style='color:#2F92EE;'>#PHP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14206, encryptionId=519b1420696, topicName=PHP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 07 00:06:50 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595465, encodeId=9d91159546573, content=<a href='/topic/show?id=0b7e824178' target=_blank style='color:#2F92EE;'>#Graphpad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8241, encryptionId=0b7e824178, topicName=Graphpad)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 11 01:06:50 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006291, encodeId=d965100629124, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP7Dz5ib9Sib6vFlVwNPib7fp8uNVA2ArzhfwjOqT01afNH5EnkyEYMibTk8uRKjg1T5oG0hyGaKl6CiaNJvRlAxYjw/132, createdBy=bbd82397376, createdName=pearcui1995, createdTime=Mon Aug 09 11:58:06 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006264, encodeId=23bc100626413, content=k, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfdf5518564, createdName=ms6000000140927326, createdTime=Mon Aug 09 10:20:30 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2022-06-07 jeanqiuqiu

    #PHP#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2069215, encodeId=f56f206921548, content=<a href='/topic/show?id=519b1420696' target=_blank style='color:#2F92EE;'>#PHP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14206, encryptionId=519b1420696, topicName=PHP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 07 00:06:50 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595465, encodeId=9d91159546573, content=<a href='/topic/show?id=0b7e824178' target=_blank style='color:#2F92EE;'>#Graphpad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8241, encryptionId=0b7e824178, topicName=Graphpad)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 11 01:06:50 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006291, encodeId=d965100629124, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP7Dz5ib9Sib6vFlVwNPib7fp8uNVA2ArzhfwjOqT01afNH5EnkyEYMibTk8uRKjg1T5oG0hyGaKl6CiaNJvRlAxYjw/132, createdBy=bbd82397376, createdName=pearcui1995, createdTime=Mon Aug 09 11:58:06 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006264, encodeId=23bc100626413, content=k, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfdf5518564, createdName=ms6000000140927326, createdTime=Mon Aug 09 10:20:30 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-11 仁医06

    #Graphpad#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2069215, encodeId=f56f206921548, content=<a href='/topic/show?id=519b1420696' target=_blank style='color:#2F92EE;'>#PHP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14206, encryptionId=519b1420696, topicName=PHP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 07 00:06:50 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595465, encodeId=9d91159546573, content=<a href='/topic/show?id=0b7e824178' target=_blank style='color:#2F92EE;'>#Graphpad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8241, encryptionId=0b7e824178, topicName=Graphpad)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 11 01:06:50 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006291, encodeId=d965100629124, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP7Dz5ib9Sib6vFlVwNPib7fp8uNVA2ArzhfwjOqT01afNH5EnkyEYMibTk8uRKjg1T5oG0hyGaKl6CiaNJvRlAxYjw/132, createdBy=bbd82397376, createdName=pearcui1995, createdTime=Mon Aug 09 11:58:06 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006264, encodeId=23bc100626413, content=k, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfdf5518564, createdName=ms6000000140927326, createdTime=Mon Aug 09 10:20:30 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-09 pearcui1995

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2069215, encodeId=f56f206921548, content=<a href='/topic/show?id=519b1420696' target=_blank style='color:#2F92EE;'>#PHP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14206, encryptionId=519b1420696, topicName=PHP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 07 00:06:50 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595465, encodeId=9d91159546573, content=<a href='/topic/show?id=0b7e824178' target=_blank style='color:#2F92EE;'>#Graphpad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8241, encryptionId=0b7e824178, topicName=Graphpad)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 11 01:06:50 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006291, encodeId=d965100629124, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP7Dz5ib9Sib6vFlVwNPib7fp8uNVA2ArzhfwjOqT01afNH5EnkyEYMibTk8uRKjg1T5oG0hyGaKl6CiaNJvRlAxYjw/132, createdBy=bbd82397376, createdName=pearcui1995, createdTime=Mon Aug 09 11:58:06 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006264, encodeId=23bc100626413, content=k, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfdf5518564, createdName=ms6000000140927326, createdTime=Mon Aug 09 10:20:30 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-09 ms6000000140927326

    k

    0

拓展阅读

苏亚虹医药科技有限公司“APL-1202中国II期临床中期分析结果”在EAU2016慕尼黑年会做现场汇报

3月12日，在德国慕尼黑举办的欧洲泌尿外科协会（EAU）2016年学术年会上，江苏亚虹医药科技有限公司展示了其正在进行的一个口服MetAP2抑制剂APL-1202的 II期临床试验的初步研究结果。应大会组委会邀请，上海复旦肿瘤医院泌尿外科戴波教授代表本次临床实验的主要研究者、上海复旦肿瘤

Baidu
map
Baidu
map
Baidu
map